CRISPR Therapeutics (CRSP) News Today

CRISPR Therapeutics AG (NASDAQ:CRSP) is seeing mixed analyst actions and partnership news today. Investors should note:

• Positive Sentiment: HC Wainwright raised its price target on CRSP to $80, maintaining a "buy" rating and implying roughly 45% upside from current levels. HC Wainwright Raises CRSP Price Target
• Positive Sentiment: Mars Inc. is leveraging CRISPR’s gene-editing technology to enhance cocoa production, showcasing potential commercial applications for CRSP’s platform. Mars Taps CRISPR Tech for Cocoa Production
• Positive Sentiment: Chardan Capital reaffirmed its "buy" rating on CRSP, signaling continued confidence in the stock’s long-term outlook. Chardan Capital Reaffirms Buy on CRSP
• Positive Sentiment: Royal Bank of Canada lifted its CRSP price target to $42, citing favorable pipeline progress. RBC Boosts CRSP Price Target
• Positive Sentiment: Brookline Capital Management edged up its Q3 2025 EPS estimate to a loss of $1.23 per share from $1.25, a slight improvement on the quarter. Brookline Raises CRSP Q3 EPS Forecast
• Positive Sentiment: Leerink Partners projects a FY2027 EPS loss of $4.53, better than the consensus of $5.16, indicating potential improvement in CRSP’s longer-term profitability trajectory. Leerink Issues FY2027 EPS Forecast
• Neutral Sentiment: Goldman Sachs reiterated its "hold" rating on CRSP, maintaining its cautious stance. Goldman Retains Hold on CRSP
• Neutral Sentiment: Zacks highlighted CRSP as a trending stock, noting increased investor attention but cautioning that fundamentals remain key. Zacks on CRSP Trend
• Neutral Sentiment: Barclays bumped its price objective to $56 but kept an "equal weight" rating, implying limited near-term upside. Barclays Lifts CRSP Target
• Negative Sentiment: Cantor Fitzgerald cut its FY2025 EPS estimate to a loss of $7.33 per share from $6.71, reflecting increased R&D spending and slower near-term commercialization. Cantor Fitzgerald Cuts CRSP FY2025 EPS Forecast
• Negative Sentiment: Leerink Partners trimmed its Q3 2025 EPS forecast to a loss of $1.62 per share from $1.59, signaling continued pressure on the upcoming quarter. Leerink Cuts CRSP Q3 EPS Forecast